Sign up Australia
Proactive Investors - Run By Investors For Investors

AusCann Group well positioned as investors move in on medical cannabis sector

The company is a vertically integrated player thanks to early-mover partnerships.
marijuana plant
The company is presenting at the upcoming ASX Small and Mid-Cap Conference

AusCann Group Holdings Ltd (ASX:AC8) is set to benefit from growing investor appetite for the medical cannabis sector.

Bloomberg recently reported that US investors are piling into an exchange-traded fund (ETF) known as ETFMG Alternative Harvest ETF which tracks the Canadian cannabis industry.

This comes as the country moves toward legalisation and liquor producers show growing interest in selling cannabis.

The US-listed $436 million cannabis ETF has taken in about $22 million in August putting it on track for the largest monthly inflow since February.

Alcohol giants teaming up with cannabis companies

Recently, alcohol giant Constellation Brands Inc (NYSE:STZ) invested $3.8 billion in Canadian marijuana maker Canopy Growth Corp (NYSE:CGC).

This is the biggest deal to date in what is now a fast emerging industry and has played a key role in turning investors’ attention to the industry.

READ: AusCann Group pilot study reveals unique capsule for cannabinoid medicines

AusCann aims to produce high quality, economical, and clinically validated cannabinoid medicines.

It has a vertically integrated strategy beginning with cultivation and production, through to manufacture and distribution of products.

This is made possible through a number of partnerships with industry leaders such as Canopy Growth Corp and Fundacion Daya.

The company is initially targeting medications for neuropathic and chronic pain in Australia and internationally, a market estimated to be worth $9 billion in Australia alone.

READ: Auscann Group raises more capital, well-funded for manufacturing cannabinoid medicines in Australia

Notably, AusCann raised around $35 million in funding recently through a placement and share purchase plan.

Upcoming ASX Small and Mid-Cap Conference

AusCann will be presenting at the inaugural ASX Small and Mid-Cap Conference being held in Sydney on Thursday, September 6.

To attend the conference, please register here.

View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use